potenti
avian
influenza
outbreak
increas
recent
year
thu
paramount
develop
novel
strategi
allevi
death
rate
show
avian
influenza
patient
exhibit
markedli
increas
serum
level
angiotensin
ii
high
serum
level
angiotensin
ii
appear
link
sever
lethal
infect
least
patient
experiment
mous
model
infect
highli
pathogen
avian
influenza
viru
result
downregul
angiotensinconvert
enzym
express
lung
increas
serum
angiotensin
ii
level
genet
inactiv
caus
sever
lung
injuri
mice
confirm
role
lung
patholog
administr
recombin
human
amelior
avian
influenza
virusinduc
lung
injuri
mice
data
link
virusinduc
acut
lung
failur
provid
potenti
treatment
strategi
address
futur
flu
pandem
avian
influenza
viru
spread
throughout
world
primarili
infect
poultri
migratori
bird
sinc
peopl
worldwid
identifi
infect
avian
influenza
viru
higher
mortal
rate
season
flu
even
spanish
flu
http
wwwwhointinfluenzahumananim
humantohuman
transmiss
virus
rare
human
infect
primarili
limit
peopl
close
contact
infect
bird
mani
virus
includ
mutat
readili
produc
strain
longer
manag
use
vaccin
current
known
antivir
drug
appar
high
lethal
infect
potenti
social
impact
make
paramount
identifi
common
molecular
diseas
mechan
well
new
treatment
option
infect
reninangiotensin
system
ra
import
role
maintain
blood
pressur
cardiac
homeostasi
fluid
salt
balanc
angiotensinconvert
enzym
ace
later
discov
sibl
share
homolog
catalyt
domain
opposit
function
ra
ace
cleav
angiotensin
gener
angiotensin
ii
key
effector
peptid
exert
multipl
biolog
function
relat
cardiovascular
renal
biolog
contrast
cleav
singl
amino
acid
residu
angiotensin
ii
gener
therebi
neg
regul
ra
reduc
angiotensin
ii
level
previou
studi
use
mice
demonstr
protect
acut
lung
injuri
ali
trigger
acid
aspir
sepsi
furthermor
identifi
essenti
vivo
receptor
sarscorona
viru
sarscov
infect
vivo
administr
sarscov
spike
protein
reduc
express
suggest
ra
involv
pathogenesi
ali
sarscov
infect
importantli
administr
recombin
proven
benefici
improv
lung
patholog
associ
sarscov
spike
acid
aspirationand
sepsisinduc
ali
differ
speci
base
data
enter
phase
ii
clinic
test
treatment
ali
human
human
infect
influenza
viru
subtyp
also
known
bird
flu
caus
sever
pneumonia
ali
ultim
result
death
owe
acut
respiratori
distress
syndrom
ard
sever
form
ali
multipl
speci
clinic
syndrom
acut
lung
failureard
observ
variou
pathogen
condit
includ
sepsi
gastric
acid
aspir
pulmonari
infect
sarscov
bird
flu
accompani
paper
observ
elev
serum
angiotensin
ii
patient
importantli
show
serum
angiotensin
ii
level
link
diseas
sever
outcom
therefor
want
determin
whether
also
involv
lung
injuri
show
play
import
role
virusinduc
ali
mice
experiment
treatment
recombin
amelior
diseas
increas
surviv
rate
follow
infect
serum
level
angiotensin
ii
increas
patient
determin
whether
ra
inde
deregul
human
sever
influenza
serum
sampl
patient
collect
divid
three
group
day
n
day
n
day
n
ill
onset
level
angiotensin
ii
marker
ra
activ
significantli
increas
avian
influenza
patient
compar
healthi
control
n
fig
tabl
data
also
indic
serum
angiotensin
ii
level
might
link
sever
lethal
bird
flu
infect
patient
fig
directli
demonstr
flu
infect
alter
ra
infect
mice
live
avian
influenza
viru
infect
mice
highli
pathogen
viru
strain
result
rapid
downregul
express
lung
h
infect
n
fig
concurr
increas
system
angiotensin
ii
level
serum
h
infect
n
per
group
fig
ace
express
appar
affect
lung
mice
fig
express
lung
serum
angiotensin
ii
level
remain
unchang
mice
challeng
less
pathogen
viru
fig
b
furthermor
sera
collect
infect
mice
day
day
show
chang
angiotensin
ii
level
correl
death
n
surviv
n
mice
fig
thu
similar
human
data
experiment
mous
model
downregul
elev
serum
angiotensin
ii
ang
ii
concentr
pg
ml
level
may
also
correl
diseas
sever
lethal
bird
flu
infect
defici
exacerb
lung
injuri
determin
whether
function
role
ali
induc
infect
live
avian
flu
virus
examin
mice
genet
defici
ref
virusinfect
mice
n
die
significantli
faster
wildtyp
control
n
fig
viral
load
detect
mice
lung
tissu
mice
significantli
higher
wildtyp
mice
lung
day
infect
n
per
time
point
fig
c
supplementari
fig
moreov
wettodri
lung
tissu
ratio
measur
lung
edema
markedli
higher
mice
day
infect
n
per
group
fig
support
hypothesi
protect
role
virusinduc
acut
lung
failur
challeng
also
result
increas
inflammatori
cell
infiltr
sever
lung
injuri
score
includ
increas
alveolar
wall
thick
format
hyalin
membran
proteinac
debri
fill
airspac
mice
n
per
group
fig
thu
genet
inactiv
express
result
lower
surviv
rate
sever
ali
follow
respiratori
infect
recombin
protect
infect
final
investig
whether
recombin
human
allevi
patholog
administr
recombin
protein
h
prior
h
day
infect
ip
mg
kg
prolong
overal
surviv
time
mice
infect
viru
fig
decreas
viral
replic
mice
lung
viral
infect
n
per
time
point
fig
supplementari
fig
weight
loss
surviv
proteintr
mice
recov
supplementari
fig
treatment
recombin
also
markedli
reduc
serum
level
angiotensin
ii
n
per
time
point
fig
develop
edema
day
infect
fig
lung
histopatholog
induc
flu
infect
also
amelior
n
fig
moreov
treatment
improv
impair
lung
function
mice
challeng
inactiv
viru
assess
via
lung
elast
supplementari
fig
note
lung
elast
reciproc
lung
complianc
measur
chang
pressur
per
unit
chang
volum
repres
stiff
lung
assess
whether
administr
recombin
also
effect
viru
infect
treat
mice
recombin
protein
h
day
day
infect
ip
mg
kg
recombin
human
amelior
ali
induc
infect
mice
supplementari
fig
studi
requir
assess
therapeut
efficaci
taken
togeth
data
show
avian
influenza
viru
infect
caus
sever
acut
lung
failur
least
part
function
alter
ra
via
express
lung
injuri
allevi
administr
recombin
human
protein
data
establish
import
role
ra
virusinduc
lung
injuri
death
discoveri
sever
acut
lung
injuri
patient
acid
aspir
sepsi
sarscov
infect
infect
virus
share
common
molecular
mechan
name
downregul
lead
ra
activ
suggest
pathogenesi
mechan
may
also
explain
caus
aliard
studi
includ
measur
supplementari
fig
bar
graph
present
quantit
analys
ace
protein
level
present
mean
aceand
n
mice
per
treatment
twotail
ttest
b
angiotensin
ang
ii
level
serum
vehicl
control
viruschalleng
mice
h
viru
vehicl
instil
angiotensin
ii
level
determin
use
radioimmunoassay
data
shown
n
mice
per
group
twotail
ttest
c
angiotensin
ii
level
sera
day
h
day
hr
infect
live
viru
tcid
angiotensin
ii
level
determin
use
radioimmunoassay
death
group
n
surviv
group
n
data
shown
twotail
ttest
experi
repeat
least
three
time
potenti
biomark
patient
previou
studi
report
protein
influenza
induc
diseas
patholog
howev
could
detect
signific
chang
mrna
protein
express
follow
overexpress
protein
pa
np
ha
na
supplementari
fig
full
blot
provid
supplementari
fig
thu
mechan
infect
result
downmodul
requir
elucid
given
flu
virus
high
mutat
rate
identif
common
regul
lung
injuri
may
also
use
allevi
aliard
owe
mutat
newli
emerg
flu
virus
includ
avian
origin
influenza
viru
andor
current
unknown
lethal
lung
pathogen
importantli
data
identifi
potenti
novel
mode
action
allevi
symptom
acut
lung
patholog
individu
infect
highli
lethal
avian
influenza
virus
influenza
virus
cell
influenza
virus
use
studi
anew
live
viru
experi
perform
biosafeti
level
facil
follow
government
institut
guidelin
anim
experi
conduct
institut
anim
care
use
committe
approv
institut
militari
veterinari
academi
militari
medic
scienc
virus
propag
via
inocul
spf
embryon
fowl
egg
via
allanto
rout
hemagglutin
allanto
fluid
collect
egg
virus
directli
use
live
virus
inactiv
use
formaldehyd
lung
elast
assay
perform
inactiv
viru
mdck
cell
cell
purchas
peke
union
medic
colleg
cell
cultur
center
cultur
dmem
gibco
supplement
fb
u
ml
penicillin
mg
ml
streptomycin
backcross
onto
background
mice
purchas
vital
river
beij
mice
hous
specif
pathogenfre
facil
lung
injuri
induc
via
intratrach
instil
allanto
fluid
af
vehicl
viru
tcid
rescu
experi
recombin
human
protein
mg
kg
apeiron
biolog
inject
intraperiton
h
prior
well
h
day
h
day
day
vehicl
control
viru
instil
assess
lung
injuri
three
four
day
instil
either
vehicl
control
flu
virus
mice
euthan
lung
remov
thorac
caviti
place
glass
vial
contain
approxim
ml
fix
formalinfix
mous
lung
embed
paraffin
coron
section
mount
glass
slide
use
standard
techniqu
section
stain
hematoxylin
eosin
mous
slide
contain
one
lung
section
examin
independ
three
pathologist
blind
treatment
genotyp
number
inflammatori
cell
count
microscop
field
lung
injuri
score
quantifi
inclus
alveolar
wall
thick
hyalin
membran
proteinac
debri
fill
airspac
give
overal
score
determin
serum
angiotensin
ii
level
blood
collect
articl
collect
time
point
via
tail
punctur
radioimmunoassay
use
measur
angiotensin
ii
serum
assess
pulmonari
edema
wet
weight
lung
determin
lung
dri
oven
h
obtain
dri
weight
surviv
data
determin
cohort
plot
kaplanmei
surviv
curv
lung
elast
measur
mice
intratrach
treat
either
vehicl
control
inactiv
viru
mg
g
anesthesia
lung
elast
measur
via
buxco
pulmonari
function
test
pft
everi
min
spontan
breath
period
h
rescu
experi
recombin
human
protein
mg
kg
intraperiton
inject
min
prior
instil
vehicl
control
viru
infect
western
blot
western
blot
lung
tissu
obtain
h
intratrach
instil
vehicl
control
virus
tcid
tissu
homogen
icecold
lysi
buffer
mm
trishcl
ph
mm
nacl
triton
mm
edta
mm
mm
naf
proteas
inhibitor
tissu
lysat
separ
sdspage
protein
transfer
onto
nitrocellulos
membran
membran
incub
antibodi
ace
bactin
follow
incub
horseradish
peroxidaseconjug
secondari
antibodi
antiac
antibodi
purchas
santa
cruz
biotechnolog
inc
antibodi
clone
r
system
antibactin
antibodi
clone
purchas
sigmaaldrich
antiflagtag
mous
mab
multisci
valid
plasmid
transfect
effici
cell
line
antibodi
purchas
bioworld
horseradish
peroxidas
hrp
conjug
secondari
antibodi
western
blot
luminol
reagent
santa
cruz
biotechnolog
antibodi
bind
visual
use
kodak
detect
system
analyz
use
quantiti
one
softwar
realtim
quantit
pcr
analysi
realtim
quantit
pcr
lung
tissu
obtain
indic
time
point
intratrach
instil
virus
tcid
cell
grown
plate
sampl
analyz
h
transfect
control
plasmid
viru
proteincod
plasmid
use
xtreme
gene
hp
dna
transfect
reagent
roch
accord
manufactur
instruct
see
supplementari
fig
list
viral
proteincod
plasmid
total
rna
lung
tissu
cell
isol
use
trizol
invitrogen
complementari
dna
cdna
synthes
mg
total
rna
high
capac
cdna
revers
transcript
kit
appli
biosystem
pcr
amplif
assay
perform
lightcycl
sybr
green
master
roch
appli
scienc
usa
lightcycl
pcr
system
pcr
product
confirm
sequenc
lung
tissu
sampl
normal
bactin
level
sampl
normal
human
glyceraldehyd
dehydrogenas
gapdh
refer
specif
primer
use
follow
forward
revers
gtcttgtctttagcc
forward
revers
mice
betaactin
forward
ctctccct
mice
betaactin
revers
forward
revers
tga
human
gapdh
forward
cggagtaacg
human
gapdh
revers
tgggtggaatcatattggaa
patient
assess
patient
sera
sera
collect
flu
patient
healthi
volunt
infect
confirm
chines
center
diseas
control
prevent
china
cdc
accord
chines
guidelin
diagnosi
treatment
human
avian
influenza
http
case
definit
human
infect
influenza
viru
http
wwwwhoint
inform
patient
healthi
volunt
use
control
present
tabl
sera
collect
china
cdc
inform
consent
obtain
studi
approv
institut
review
board
china
cdc
angiotensin
ii
level
sera
determin
use
elisa
accord
manufactur
instruct
rapidbio
lab
angiotensin
ii
valu
patient
shown
scatter
diagram
bar
repres
median
valu
data
analyz
use
mannwhitney
u
test
mous
data
shown
mean
valu
sem
measur
singl
time
point
analyz
use
anova
demonstr
signific
analyz
use
twotail
ttest
time
cours
analyz
use
repeat
measur
mix
model
anova
bonferroni
postttest
statist
test
perform
use
graphpad
prism
graphpad
softwar
san
diego
ca
usa
consid
indic
statist
signific
